Science Daily: Pharmacology News

MARCH 27, 2024

Those with aging immune systems struggle to fight off novel viruses and respond weakly to vaccination. Researchers were able to revitalize the immune system in mice.

Vaccine 312

Vaccine Virus Research 312

Drugs.com

OCTOBER 18, 2024

18, 2024 -- A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization.With U.S. vaccination rates falling, "I. FRIDAY, Oct.

Vaccine 264

Vaccine Virus 264

Drugs.com

JULY 9, 2024

TUESDAY, July 9, 2024 -- Expectant mothers who get vaccinated to protect their newborns against respiratory syncytial virus (RSV) are not putting themselves or their babies at risk, new research affirms. It found that getting the shot during late.

Vaccine 264

Vaccine Virus Research 264

Drugs.com

SEPTEMBER 4, 2024

4, 2024 -- Current vaccines against mpox were designed to fight an older, rarer cousin of the virus, smallpox.Now, new research from the drug company Moderna suggests its new mpox vaccine, based on mRNA technology, might do a. WEDNESDAY, Sept.

Vaccine 246

Vaccine Trials Virus Research 246

Drugs.com

JUNE 10, 2024

Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV) vaccine for people in their 50s who are at increased risk for the illness. MONDAY, June 10, 2024 -- The U.S. Drugmaker GSK's.

Vaccine 264

Vaccine Virus FDA Drugs 264

Drugs.com

JULY 9, 2024

TUESDAY, July 9, 2024 -- Expectant mothers who get vaccinated to protect their newborns against respiratory syncytial virus (RSV) are not putting themselves or their babies at risk, new research affirms.It found that getting the shot during late.

Vaccine 246

Vaccine Virus Research 246

Drugs.com

OCTOBER 18, 2024

18, 2024 -- A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. vaccination rates falling, "I. FRIDAY, Oct.

Vaccine 246

Vaccine Virus Hospitals 246

Drugs.com

JUNE 10, 2024

Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV) vaccine for people in their 50s who are at increased risk for the illness. MONDAY, June 10, 2024 -- The U.S. Drugmaker GSK's.

Vaccine 246

Vaccine Virus FDA Drugs 246

Drugs.com

JUNE 29, 2023

THURSDAY, June 29, 2023 -- Americans ages 60 and up can get their vaccine for respiratory syncytial virus (RSV) this fall, the U.S. Centers for Disease Control and Prevention announced Thursday. On Thursday, Dr. Rochelle Walensky, the outgoing CDC.

Vaccine 290

Vaccine Virus Disease 290

Drugs.com

AUGUST 28, 2023

28, 2023 -- About half of older adults (52 percent) have heard of the new vaccines against respiratory syncytial virus (RSV), Arexvy and Abrysvo, according to the National Poll on Healthy Aging released online on Aug. MONDAY, Aug. The poll,

Vaccine 279

Vaccine Virus 279

Drugs.com

APRIL 16, 2024

TUESDAY, April 16, 2024 -- Genetics-based “one-and-done” vaccines for the flu and COVID could prove more effective and easier to craft than current jabs, researchers report.These new vaccines would target viruses using a different response to.

Vaccine 246

Vaccine Virus Research 246

BioPharma Drive: Drug Pricing

JULY 27, 2023

GSK expects its respiratory syncytial virus vaccine will be a multibillion dollar product. But at the beginning it’s predicting a slower launch than for its fast-selling shingles shot.

Vaccine 246

Vaccine Virus Production 246

Drugs.com

SEPTEMBER 7, 2023

7, 2023 -- While it doesn't prevent infection altogether, new research shows the mpox vaccine does reduces the severity of disease in those who fall ill from the virus. THURSDAY, Sept. An international team of scientists found that those people who.

Vaccine 214

Vaccine Virus International Disease 214

Drugs.com

SEPTEMBER 22, 2023

22, 2023 -- Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus (RSV). FRIDAY, Sept. Following approval one month ago by the U.S. Food and Drug Administration, the Centers for.

Vaccine 214

Vaccine Virus Drugs 214

BioPharma Drive: Drug Pricing

DECEMBER 12, 2023

The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses.

Vaccine 196

Vaccine Pharma Companies Virus 196

Drugs.com

AUGUST 22, 2023

22, 2023 -- Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus (RSV), following U.S. TUESDAY, Aug. Food and Drug Administration approval of the shot, called Abrysvo, on.

FDA Approval 189

FDA Approval Vaccine Virus FDA 189

Drugs.com

AUGUST 22, 2023

22, 2023 -- Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus (RSV), following U.S. TUESDAY, Aug. Food and Drug Administration approval of the shot, called Abrysvo, on.

Vaccine 189

Vaccine FDA Approval Virus FDA 189

Drugs.com

APRIL 17, 2025

THURSDAY, April 17, 2025 A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including respiratory syncytial virus (RSV), meningitis and a mosquito-borne illness called chikungunya.The panel, k.

Vaccine 130

Vaccine Virus Disease 130

Drugs.com

DECEMBER 18, 2023

18, 2023 -- Most parents plan to have their kids vaccinated against influenza and respiratory syncytial virus (RSV), even as COVID-19 vaccine acceptance flags, a new poll finds.Seven in 10 parents (71%) plan to have their children get. MONDAY, Dec.

Vaccine 173

Vaccine Virus 173

Drugs.com

JUNE 9, 2023

Food and Drug Administration advisory panel on Thursday recommended that the agency approve an RSV vaccine for infants and some toddlers. The monoclonal antibody shot would protect against respiratory syncytial virus. FRIDAY, June 9, 2023 – A U.S.

Vaccine 130

Vaccine FDA Virus Drugs 130

Drugs.com

JUNE 29, 2023

THURSDAY, June 29, 2023 -- Americans ages 60 and up can get their vaccine for respiratory syncytial virus (RSV) this fall, the U.S. Centers for Disease Control and Prevention announced Thursday. On Thursday, Dr. Rochelle Walensky, the outgoing CDC.

Vaccine 130

Vaccine Virus Disease 130

Drug Target Review

AUGUST 11, 2023

In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. Since December 2019, SARS-CoV-2 (COVID-19) infection has become a worldwide urgent public health concern.

Vaccine 98

Vaccine Immune Response Bioinformatics Virus 98

SCIENMAG: Medicine & Health

JUNE 28, 2023

A University of Queensland developed vaccine will protect farmed saltwater crocodiles from West Nile virus (WNV), providing economic and biodiversity benefits to northern Australia.

Vaccine 91

Vaccine Virus 91

Drug Discovery Today

DECEMBER 5, 2020

OVO Biomanufacturing, a spin-out from the University of Warwick and Coventry University, is developing digital solutions to improve the efficiency of viral vaccine and gene therapy manufacture. The technology can be applied to any virus that is grown to produce a vaccine or therapy.

Vaccine 100

Vaccine Therapies Virus Production 100

Chemical Biology and Drug Design

NOVEMBER 13, 2023

Challenges involved in vaccines formulation were also featured. Use of computational methods and models for vaccine development has revolutionized the traditional methods of vaccine development. Main role of mRNA vaccines in the COVID-19 challenge was discussed.

Vaccine 100

Vaccine Laboratories RNA Clinical Development 100

DrugBank

MARCH 12, 2025

The COVID-19 pandemic brought mRNA to global prominence by developing highly effective vaccines by Moderna and Pfizer-BioNTech. However, mRNA technology has introduced new possibilities, particularly in developing personalized cancer vaccines and combination therapies. Another challenge is the potential for unintended immune responses.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

The Pharma Data

AUGUST 27, 2020

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . Each patient was given two 100 microgram doses of the vaccine 28 days apart. These antibodies were higher than those seen in people who had recovered from the virus.

Vaccine 90

Vaccine Immune Response Clinical Trials Virus 90

The Pharma Data

AUGUST 13, 2020

The UK government has signed deals for a further 90 million doses of coronavirus vaccine. The vaccines are being developed by the Belgian pharmaceutical company Janssen and the US biotech company Novavax. It means the UK has placed orders for six experimental vaccines, taking its potential stockpile to 340 million doses.

Vaccine 52

Vaccine Virus Government Clinical Trials 52

SCIENMAG: Medicine & Health

JANUARY 9, 2024

Vaccines teach the adaptive immune system about new pathogens without having to go through an actual infection. Humans are protected by two branches of the immune system. This has greatly contributed […]

Vaccine 79

Vaccine Virus 79

SCIENMAG: Medicine & Health

AUGUST 20, 2023

Research at a Glance: A Murdoch Children’s Research Institute-led review has found COVID-19 vaccines are effective against severe cases of the disease in children and adolescents.

Vaccine 75

Vaccine Virus Disease Research 75

SCIENMAG: Medicine & Health

AUGUST 22, 2023

The first Americans over age 60 just started rolling up their sleeves to get vaccinated against respiratory syncytial virus, or RSV, now that brand-new vaccines have started to arrive at pharmacies and clinics.

Vaccine 68

Vaccine Pharmacy Virus 68

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Vaccine 52

Vaccine Virus Immune Response Clinical Trials 52

Eye on FDA

DECEMBER 15, 2021

We are long gone from the days of being threatened by a rampant Alpha virus to having several successive variants. We now have multiple vaccines – mRNA and traditional in the U.S. However there is also an alarming rise among people who have completed their primary vaccination. and an even greater array outside the U.S.

Vaccine 72

Vaccine Nurses Virus Treatment 72

The Pharma Data

JANUARY 21, 2021

President Joe Biden has promised to re-energize the nation’s response to COVID-19, but one of his top pandemic advisors says that effort could be hamstrung by both the virus and the failings of the previous administration. Right now, the main focus is on helping distribute the vaccines, Osterholm said.

Vaccine 52

Vaccine Virus RNA Research 52

SCIENMAG: Medicine & Health

JULY 24, 2023

A new paper in Biology Methods & Protocols, published by Oxford University Press, shows it may be possible to design vaccines that will induce a stronger immune response to infecting pathogens, such as the virus causing COVID-19.

Vaccine 60

Vaccine Bioinformatics Immune Response Virus 60

The Pharma Data

MAY 26, 2023

With support from the PIP Partnership Contribution, the workshop conducted in March 2023 in La Paz involved a simulation exercise in the form of a specialized board game – a unique and innovative approach to testing key response operations – aimed at reviewing and analyzing their National Deployment and Vaccination Plan.

Virus 52

Virus Vaccine Production 52

The Pharma Data

NOVEMBER 27, 2020

Vaccine development to cure coronavirus is at an all-time high after Pfizer and BioNTech announced they had success with a possible vaccine candidate. UK firm develops solution for identifying whether patients are actually infectious from a virus or not. Read on to for the full insight.

Vaccine 52

Vaccine Virus International Immune Response 52